AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02242526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodesign™ Surgisis® Graft, Cook Medical, Bloomington
Description: Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.
Study NCT02853357 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment
Study NCT02853357 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Core Strengthening Exercises
Description: Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
Study NCT02853357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Strengthening Exercises
Description: Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
Study NCT02319525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized patient decision-aid
Description: The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.
Study NCT02319525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (lupus pamphlet)
Description: Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology \[ACR\]) regarding lupus and its treatments, that explained risks and benefits of various treatments
Study NCT03609853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vapor (distilled water)
Study NCT03609853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC, limonene, or THC and limonene
Description: Acute drug exposure
Study NCT04246320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal directed therapy (GDT)
Description: Goal directed therapy (GDT) hemodynamic management (MAP > 60 mmHg) and processed EEG-guided anesthesia (PSI targeted between 30-50).
Study NCT00882427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced model predictive control algorithm (eMPC)
Description: eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
Study NCT03754413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental
Description: Neuramis® Deep Lidocaine
Study NCT03754413 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: comparator
Description: No-treatment
Study NCT04681547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genicular nerve Block
Description: After the administration of spinal anesthesia, the anatomical structures of the proximal and distal region of the knee will be explored through an M- ultrasound machine Turbo® with a high-frequency 6-13 MHz linear probe.~The ultrasound transducer will be placed in a coronal orientation to the axis of the knee in the corresponding area to be blocked according to anatomical landmarks of superior medial genicular nerve (SMGN), inferior medial genicular nerve block (IMGN), superior lateral genicular nerve (SLGN), inferior lateral genicular nerve (ILGN), and recurrent genicular nerve (RGN).~It should be noted that the visualization of the genicular arteries in the femoral epicondyles and in the area of the tibial plateau, represents an accurate guide to where the sensory afferents are, however; its display is not constant.~4 ml of 0.2% ropivacaine will be administered, with adrenaline 1: 100 000 in each of the five nerves.
Study NCT04681547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration Analgesia
Description: 100 ml of ropivacaine 0.2% with 1 mg of epinephrine during the period of intraoperative ischemia and, before the closure of the surgical wound, 50 ml of ropivacaine 0.2%.
Study NCT01366495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Bridge
Description: Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
Study NCT03475095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuina
Description: Patients will receive Tuina therapies tiwce per week in one month.each time lasts about 20 minutes,a total of 4 weeks.
Study NCT04196153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle screws instrumentation
Description: The screws are inserted in two or more consecutive levels to prevent motion at the segments that are being fused. It will be done using one of the two guidance technique depending on which arm the patient will be randomized to.
Study NCT01100619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later
Study NCT01100619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: dosed with capsules daily
Study NCT03824769 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Maintenance + Healthy Thinking
Description: Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
Study NCT03824769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Maintenance Treatment + Future Thinking
Description: Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
Study NCT02260687 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Administration by intravitreal injection
Study NCT03714204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation technique
Description: The TM technique is a simple mental procedure that is categorized in the automatic self-transcending category of meditation practices. It is automatic in that it does not involve any concentration or control. It allows the mental activity to settle down in a spontaneous and natural manner during a process called transcending, or going beyond, until it reaches a state beyond conscious thinking. Correspondingly, the body settles down to a deep state of rest which allows stress to dissolve and the nervous system to rejuvenate The effortless nature of the TM practice coupled with the vast research supporting its efficacy, its systematic standardized teaching program and the fact that it does not involve any belief or change in one's lifestyle made it the choice intervention for this research.
Study NCT03774251 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma Injection
Description: The patient will undergo a single platelet-rich plasma peritendinous injection
Study NCT03774251 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shock Wave Therapy
Description: The patient will undergo a series of three extracorporeal shock wave therapy treatments to the lateral hip
Study NCT01246934 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: ASR METHOD
Study NCT01313689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab IV, initial dose 300 mg, followed 1 week later with 2000 mg once weekly for 7 weeks, followed 4 weeks later by one infusion of 2000 mg every 4 weeks for 4 infusions, for a total of 12 infusions over 24 weeks. After 24 weeks of ofatumumab treatment, patients who have achieved at least stable disease or better, and whom the investigator would deem appropriate for the therapy to continue, would undergo a second randomisation (2:1) to either 1) an additional ofatumumab dose regimen of 2000 mg once every 4 weeks for up to an additional 24 weeks, or 2) no further therapy (i.e. observation only).
Study NCT01313689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physicians' Choice
Description: Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
Study NCT01959022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin XL
Description: Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
Study NCT02991131 — intervention group
Intervention type: DRUG
Intervention: Tedizolid (Sivextro, BAY1192631)
Description: Antibiotic
Study NCT02991131 — intervention group
Intervention type: DRUG
Intervention: Linezolid
Description: Antibiotic
Study NCT01337115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNB plus CFNB
Description: A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
Study NCT01337115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CFNB
Description: A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
Study NCT04160767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Vivomixx
Description: VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
Study NCT04160767 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Gluten free diet
Description: Gluten free diet will be encouraged in both arms
Study NCT04160767 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: Gluten free diet will be encouraged in both arms
Study NCT04160767 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
Study NCT03369990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin type A(DWP450)
Study NCT05087004 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen Council
Description: Youth randomly selected for Teen Council attended weekly meetings for an entire school year to receive training on specific topics. In turn, they provided educational presentations to the community, which required that they miss school (about one day per month). The presentations Teen Council members offered in middle and high schools were most commonly on birth control methods; relationships; reproductive anatomy and physiology; sexual diversity; STDs/STIs; sexual consent; HIV/AIDS; and abstinence.
Study NCT02368587 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: WJMSCs Vs. placebo
Description: WJMSCs Vs. placebo
Study NCT02368587 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: WJMSCs Vs. placebo
Study NCT01458392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalantercept
Description: Subcutaneous dose of dalantercept once every 3 weeks.
Study NCT01597804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infection Prophylaxis and Management
Description: Undergo preoperative preparation with the Bathing Bundle
Study NCT04698863 — intervention group
Intervention type: DEVICE
Intervention: Oxygen reserve index
Description: eveluating oxygen reserve in blood
Study NCT01697670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with Gliolan
Description: Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
Study NCT01744262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia
Description: Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5\~4 µg/mL and remifentanil effect site concentration 2\~5 ng/mL.
Study NCT01744262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation Anesthesia
Description: Anesthesia induction with intravenous propofol bolus of 1.5\~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5\~2.0 % and remifentanil effect site concentration 2\~5 ng/mL.
Study NCT03369990 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline
Study NCT03772444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: Patients will drink 70 ml of beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
Study NCT03772444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted beetroot juice
Description: Patients will drink 70 ml of nitrate-depleted beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
Study NCT03772444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Water
Description: Patients will drink 70 ml of water in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
Study NCT00609765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Every 28 Days: Avastin 5mg/kg iv days 1 and 15
Study NCT00609765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Every 28 Days: Fluorouracil 400mg/m\^2 iv bolus daily days 1-5
Study NCT00609765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Every 28 Days: Doxorubicin 40mg/m\^2 iv bolus day 1
Study NCT00609765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptozocin
Description: Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
Study NCT00609765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Premedication: Dexamethasone 20mg intravenously days 1-5
Study NCT00609765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Premedication: Ondansetron 16mg intravenously days 1-5
Study NCT01943409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: soybean oil-based lipid emulsion
Study NCT01943409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClinOleic
Description: olive oil-based lipid emulsion
Study NCT03631160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAES treatmen
Description: In the acupoints group patients are treated with low-frequency pulse electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) at SP6 and BL 32 points during the operation in the operating room ,and at CV3 and CV4 acupoints for 45 minutes in postanesthesia Care Unit. After Deqi, electroacupuncture stimulation apparatus is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 \~ 30 milliamp (mA) (gradually increase to the patient's maximum tolerance) and maintained until the end of treatment.
Study NCT03631160 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TAES treatmen
Description: Participants in the acupoints group receive shallow acupointing at SP6, BL 32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm).Specifically, the acupoint is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output .
Study NCT02783521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling sessions
Description: During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.
Study NCT02783521 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait List Control
Description: After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
Study NCT02733393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion (SPG) Block
Description: Patients who are undergoing a thoracotomy will be informed that they may develop moderate to severe postoperative ISP and may have the option to receive an SPG block. The SPG block will be performed every three minutes for 20 minutes, 0.1mL of the 4% lidocaine will be administered through. After 20 minutes and various intervals thereafter the patient will be asked to rate their shoulder pain.
Study NCT02733393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Study NCT03841682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CARE2
Description: I-CARE2 intervention synergistically integrates 2 proven national programs: the Program to Encourage Active and Rewarding Lives (PEARLS) for depression care and the Group Lifestyle Balance (GLB) program for weight loss and cardiometabolic risk reduction.~The PEARLS program provides problem-solving therapy (PST) as first-line for treating depression, with as-needed antidepressant medication intensification. Adapted from the original Diabetes Prevention Program, the GLB program promotes healthy lifestyle change for weight loss and increased physical activity.